Petros Pharmaceuticals, Inc. (PTPI)
Market Cap | 3.66M |
Revenue (ttm) | 3.85M |
Net Income (ttm) | -21.98M |
Shares Out | 2.11M |
EPS (ttm) | -10.64 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 54,389 |
Open | 1.51 |
Previous Close | 1.50 |
Day's Range | 1.48 - 1.75 |
52-Week Range | 0.92 - 9.54 |
Beta | 1.98 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 14, 2023 |
About PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health... [Read more]
Full Company ProfileFinancial Performance
In 2022, PTPI's revenue was $5.99 million, a decrease of -23.29% compared to the previous year's $7.81 million. Losses were -$20.04 million, 123.0% more than in 2021.
Financial StatementsNews

Petros Pharmaceuticals to Present at the LD Micro Main Event XVI
NEW YORK, NY / ACCESSWIRE / September 28, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway, announ...

Petros Pharmaceuticals Provides Letter to Shareholders
NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provide...

Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, NY / ACCESSWIRE / September 6, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a pioneer in expanding consumer access to medication through over the counter (OTC) pathways, announces toda...

Petros Pharmaceuticals Announces Capital Raise of $15 Million
Provides Update on Progress Toward Over the Counter (non-prescription) Development of STENDRA NEW YORK, NY / ACCESSWIRE / July 13, 2023 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or "the C...

Petros Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on December 1, 2022 NEW YORK, NY / ACCESSWIRE / November 30, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (Nasdaq:PTPI), a le...

Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update
NEW YORK, NY / ACCESSWIRE / November 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial r...

New FDA-Approved Labeling for Petros Pharmaceuticals' STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy
Expanded STENDRA Labeling Now Includes Data on a Significant Population of Men Not Previously Included Following Submission of Additional Clinical Trial Data NEW YORK, NY / ACCESSWIRE / October 25, 20...

Petros Pharmaceuticals to Participate in Two October 2022 Conferences
NEW YORK, NY / ACCESSWIRE / October 21, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offi...

Internationally Published, Head-to-Head Data From India of Petros Pharmaceuticals' STENDRA(R) (Avanafil) Tablets Reported Improvement in Erectile Function Compared to Sildenafil and Baseline After 12 Weeks of Therapy
Data Published in the "International Journal of Urology" Also Showed Secondary Endpoints, Such as Onset of action in 15 Minutes and Percentage of Patients Reaching Normal Erectile Function According t...

Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022
NEW YORK, NY / ACCESSWIRE / August 15, 2022 / Petros Pharmaceuticals, Inc. ("Petros" or "the Company") (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announced financial res...

Petros Pharmaceuticals Responds to Fraudulent Press Release
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today confirmed that a press release issued on July 28, 20...

Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share
Petros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company's healthcare platform

Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky
Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health Category and STENDRA® (avanafil) Dr. Drew to Raise Awareness of Petros Pharmaceuticals' Mission in The Men's Health C...

Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced financial resul...

Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company's Novel Topical Investigational Treatment for Peyronie's Disease Which Impacts More Than 1 in 10 Men in the US
Company Is Developing H-100 as Potentially the First FDA-Approved, Nanoparticle-Based Topical Treatment Designed to Provide Improved and Sustained Local Medication Permeation Against Peyronie's Diseas...

Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offic...

Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology
Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially Allowing Biosensor Feedback of Erectile Device Therapy Sensor Measures Oxygen Levels Within Specific Human Tissue, Potentially A...

Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights
NEW YORK, April 01, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces financial res...

Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference
NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, announces today that President and Chief Commercial Offic...

Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health
NEW YORK, Feb. 1, 2022 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announces that it has signed a collaboration agreement wi...

5 Short Squeeze Candidates To Watch: Insignia Systems, American Virtual Cloud Top List Again, Reliance Global Rejoins
Potential short squeeze plays gained steam in 2021 with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.

Petros Pharmaceuticals Announces Closing of $7.5 Million Offering
NEW YORK, Dec. 28, 2021 Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offe...
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter Leaderboard
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile ...

Petros Pharmaceuticals Announces $7.5 Million Offering
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that it has entered into definitive agreements...

5 Short Squeeze Candidates To Watch: Petros Pharmaceuticals, iSpecimen Top The List Again
Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge movie. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile...